Celanese inks agreement with the Population Council to supply its VitalDose drug delivery platform

The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades

Philips extends its mobile C-arm range with Zenition 30

Alleviating staff shortages by empowering surgeons with greater personalization and control

AI to transform all processes in drug development by 2026, predicts CPHI Report

In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran

Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension

Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris

Global health challenges can be resolved using digital technology: Dr Alain Labrique

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Elekta and IAEA partner to improve access to cancer care in underserved countries

Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden

Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales

Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year